Human VEGF/VEGFA DTSet enzyme-linked immunoassay kit
| Specification | 96*5 Test；96T*15 Test |
|---|---|
| Standard Curve Range | 31.25 pg/ml -2000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl |
| Type | Not Ready-to-Use |
| Test Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0416 | 0.0415 | 0.0416 | |
| 31.25 | 0.2065 | 0.1766 | 0.1916 | 0.1500 |
| 62.50 | 0.3067 | 0.3041 | 0.3054 | 0.2639 |
| 125.00 | 0.6734 | 0.5934 | 0.6334 | 0.5919 |
| 250.00 | 1.0553 | 0.9815 | 1.0184 | 0.9769 |
| 500.00 | 1.8868 | 1.8122 | 1.8495 | 1.8080 |
| 1000.00 | 3.1508 | 3.1734 | 3.1621 | 3.1206 |
| 2000.00 | 4.1827 | 4.1689 | 4.1758 | 4.1343 |
Product Features
- Optimized capture and detection antibody pairings with recommended concentrations save lengthy development time
- Development protocols are provided to guide further assay optimization
- Assay can be customized to your specific needs
- Economical alternative to complete kits
Kit Content
- Capture Antibody
- Detection Antibody
- Recombinant Standard
- Streptavidin conjugated to horseradish-peroxidase (Streptavidin-HRP)
Other Reagents Required
DTSet Ancillary Reagent Kit (5 plates): containing 96 well microplates, plate sealers, substrate solution, stop solution, plate coating buffer (PBS), wash buffer, and assay buffer.
- 96 well microplates: YOUKE Life, Catalog # DSEP01. Plate Sealers: YOUKE Life, Catalog # DSSF01.
- Coating Buffer: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2-7.4, 0.2μm filtered . YOUKE Life, Catalog # DSCB01.
- Blocking Buffer: YOUKE Life, Catalog # DSBB01.
- Wash Buffer: 0.05% Tween® 20 in PBS, pH 7.2-7.4. YOUKE Life, Catalog # DSWB01.
- Assay Buffer: 0.5% BSA，0.05% Tween® 20，PBS Solution.YOUKE Life, Catalog # DSAB01
- Substrate Solution: Tetramethylbenzidine. YOUKE Life, Catalog # DSTS01.
- Stop Solution: 0.5mol/ml H2SO4. YOUKE Life, Catalog # DSSS01.
Product Data Sheet
Background: VEGF/VEGFA
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues in a cystine knot structure and the formation of antiparallel disulfide-linked dimers. Humans express alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. Isoforms other than VEGF121 contain basic heparin-binding regions and are not freely diffusible. Human VEGF165 shares 88% aa sequence identity with corresponding regions of mouse and rat VEGF. VEGF is expressed in multiple cells and tissues including skeletal and cardiac muscle, hepatocytes, osteoblasts, neutrophils, macrophages, keratinocytes, brown adipose tissue, CD34+ stem cells, endothelial cells, fibroblasts, and vascular smooth muscle cells. VEGF expression is induced by hypoxia and cytokines such as IL-1, IL-6, IL-8, oncostatin M, and TNF-alpha. VEGF isoforms are differentially expressed during development and in the adult.
VEGF dimers bind to two related receptor tyrosine kinases, VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR), and induce their homodimerization and autophosphorylation. These receptors have seven extracellular immunoglobulin-like domains and an intracellular split tyrosine kinase domain. They are expressed on vascular endothelial cells and a range of non-endothelial cells. Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity. VEGF165 also binds the semaphorin receptor, neuropilin-1, which promotes complex formation with VEGF R2.
VEGF is best known for its role in vasculogenesis. During embryogenesis, VEGF regulates the proliferation, migration, and survival of endothelial cells, thus regulating blood vessel density and size, but playing no role in determining vascular patterns. VEGF promotes bone formation through osteoblast and chondroblast recruitment and is also a monocyte chemoattractant. After birth, VEGF maintains endothelial cell integrity and is a potent mitogen for micro- and macro-vascular endothelial cells. In adults, VEGF functions mainly in wound healing and the female reproductive cycle. In diseased tissues, VEGF promotes vascular permeability. It is thus thought to contribute to tumor metastasis by promoting both extravasation and tumor angiogenesis. Various strategies have been employed therapeutically to antagonize VEGF-mediated tumor angiogenesis. Circulating VEGF levels correlate with disease activity in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.
